相关实验视频
Updated: May 6, 2026

10:37
Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
21.9K
血-血复合物的抗凝活性的结构基础
P Fuentes-Prior1, Y Iwanaga, R Huber
1Max-Planck-Institut für Biochemie, Martinsried, Germany. fuentes@biochem.mpg.de
Nature
|April 13, 2000
概括
结合α-血素的血栓模块素 (TME456) 通过改变基质特异性来防止血液凝结. 这种结构洞察力揭示了TME456如何促进抗凝蛋白C的激活,而不会改变血栓活性部位.
科学领域:
- 生物化学 生物化学
- 结构生物学 结构生物学
- 血液学 血液学 血液学
背景情况:
- 阿尔法血是血液凝固的关键酶,促进血块的形成.
- 血栓模块素调节血栓的活性,通过激活蛋白C,将其转向抗凝.
- 活性蛋白C通过降解活性因子V和VIII来调节凝血级联.
研究的目的:
- 为了确定与TME456血栓模块片段结合的人类α-的晶体结构.
- 阐明血栓模块素改变血栓的基质特异性的机制.
主要方法:
- 在2.3A分辨率的α-氨酸-TME456复合物的X射线晶体学.
- 一个蛋白质C模型的分子对接到复合体.
主要成果:
- 形状为Y的TME456片段与血栓素的离子结合的外-I结合,从而在固体上阻碍了前凝基质的进入.
- 在TME456结合后,血激素的活性部位结构基本保持不变.
- 接表明,TME456最佳地定位了蛋白C,以使未改变的血栓活性部位激活.
结论:
- 该结构揭示了血栓模块素如何与外-I结合,将血栓素的功能从促凝剂重定向到抗凝剂.
- 这种机制涉及益血凝剂基质的全抑制和蛋白C的最佳呈现以激活.
更多相关视频
相关概念视频
Intracellular Signaling Affects Focal Adhesions
2.8K
Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
Some...
2.8K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.8K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.8K
Coagulation
8.5K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
8.5K
Extrinsic and Intrinsic Pathways of Hemostasis
11.0K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
11.0K
Clot Retraction and Fibrinolysis
6.1K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.1K

